The Delhi High Court has dismissed AbbVie’s appeal regarding the refusal of their patent application for an anti-cMet antibody-drug conjugate. The court found the proposed amendments exceeded permissible scope under the Indian Patents Act.
Read more about AbbVie’s Patent Refusal Upheld over Impermissible Shift from Treatment to Product Claims